Insilico Medicine

About Insilico Medicine

Financials

Dated, source-cited figures. Estimates are marked.

Products by Insilico Medicine

All products by Insilico Medicine reviewed by our AI panel of experts.

Insilico MedicineAI Healthcare

Generative AI platform for end-to-end drug discovery and development

Free7.7/10

How Our Review Panel Scores Insilico Medicine

Six independent reviewer personalities assessed Insilico Medicine's product on their own terms. They disagreed by 2.2 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Insilico Medicine competes with, and how they differ.

Recursion7.4/10

Recursion (Nasdaq: RXRX) runs industrial-scale phenotypic screening across a large internal pipeline and, after absorbing Exscientia in late 2024, added structure-based small-molecule design — a broader in-house tech stack than Insilico's target-ID-to-molecule generative pipeline, but without a Phase 3 asset yet.

1 product reviewed on TopReviewed

Atomwise7.3/10

Atomwise licenses its AtomNet convolutional neural network for virtual screening to pharma partners on a fee/royalty basis rather than advancing its own clinical pipeline — a pure technology-licensing model versus Insilico's in-house drug development through Phase 3 and public listing.

1 product reviewed on TopReviewed

X

XtalPi

XtalPi (HKEX: 2228), also Hong Kong-listed and AI-plus-robotics driven, operates primarily as a fee-for-service R&D partner across pharma, agrochemical and materials clients rather than owning clinical assets — a CRO-style model versus Insilico's internally-owned, Phase 3-stage drug pipeline.

Company Timeline

Key milestones in Insilico Medicine's history, with sources.

1. Jul 7, 2026Milestone

   Phase III trial initiated for rentosertib in IPF

   Insilico initiated a Phase III trial (320 patients, 47 centers across China; 52-week primary endpoint of annualized FVC decline) for rentosertib, its lead AI-discovered, AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis — the first AI-discovered foundation-stage drug candidate to reach pivotal-stage evaluation.

   insilico.com
2. Jun 17, 2026Milestone

   First-in-human dosing completed for Parkinson's candidate ISM8969

   Insilico completed first-in-human dosing in a Phase 1 trial (Australia, 80 healthy participants plus 20 at cardiovascular risk) for ISM8969, its brain-penetrant NLRP3 inhibitor for Parkinson's disease and chronic neuroinflammation.

   news-medical.net
3. Jan 21, 2026Partnership

   Hygtia Therapeutics deal for NLRP3 inhibitor ISM8969

   Insilico agreed to co-develop brain-penetrant NLRP3 inhibitor ISM8969 (designed via its Chemistry42 platform) with Chinese biotech Hygtia Therapeutics — $10M upfront plus up to $56M in milestones, with Insilico leading the drug into Phase 1 for Parkinson's disease.

   fiercebiotech.com
4. Dec 30, 2025Funding

   Hong Kong Stock Exchange IPO (3696.HK) — $293M raised

   Insilico Medicine listed on the HKEX Main Board (ticker 3696.HK), the first AI-driven biotech to do so under Chapter 8.05, raising roughly $293M (~HK$2.3B) from the sale of 94.7 million shares; shares rose 24.7% on debut, valuing the company at HK$16.7B (~$2.1B). Cornerstone investors included Eli Lilly, Tencent and Temasek.

   insilico.com
5. Jun 3, 2025Milestone

   Nature Medicine publishes positive Phase IIa results for rentosertib

   Insilico and collaborators published Phase IIa trial results for rentosertib (ISM001-055) in Nature Medicine: at the 60mg once-daily dose, FVC improved by +98.4 mL over 12 weeks versus a -20.3 mL decline on placebo, in 71 IPF patients across 22 China sites.

   nature.com
6. March 2025Funding

   Series E — $110M, crosses $1B unicorn valuation

   Insilico Medicine raised $110 million in Series E financing led by Hong Kong asset manager Value Partners Group, pushing its valuation above $1 billion.

   forbes.com
7. Jun 6, 2022Funding

   Series D — $60M led by Warburg Pincus

   Insilico Medicine raised $60 million in Series D financing led by Warburg Pincus (continuing from Series C), with new investor BHR Partners, to fund pipeline advancement and an AI-driven robotic drug discovery laboratory.

   prnewswire.com
8. Feb 24, 2022Milestone

   AI-discovered, AI-designed IPF drug (ISM001-055) enters Phase 1

   Insilico's anti-fibrotic small-molecule inhibitor ISM001-055 (later rentosertib), targeting TNIK for idiopathic pulmonary fibrosis, entered Phase 1 trials 30 months after program start — an early industry proof point for AI-native drug discovery.

   insilico.com
9. Jan 11, 2022Partnership

   Strategic AI drug discovery collaboration with Fosun Pharma

   Shanghai Fosun Pharmaceutical and Insilico Medicine entered a collaboration to jointly advance AI-driven drug discovery on multiple biological targets, including co-development of Insilico's QPCTL program.

   prnewswire.com
10. Jun 22, 2021Funding

    Series C — $255M led by Warburg Pincus

    Insilico Medicine raised $255 million in a Series C round led by Warburg Pincus, taking cumulative funding since its 2014 inception to over $310 million.

    prnewswire.com
11. Sep 10, 2019Funding

    Series B — $37M led by Qiming Venture Partners

    Insilico Medicine closed a $37 million Series B round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital and BOLD Capital Partners.

    en.prnasia.com
12. 2014Founded

    Insilico Medicine founded by Alex Zhavoronkov

    Insilico Medicine was founded in 2014; Deep Knowledge Ventures provided seed funding the same year. The company grew into an end-to-end AI-driven drug discovery firm with hubs in Hong Kong, Boston/Cambridge MA, Shanghai and Abu Dhabi.

    prnewswire.com